Tag: AZ

January 4, 2023

The start of the trial triggers a $5m milestone payment from AZ, which licensed AZD3152 from RQ Bio in May last year, and reinforces the financial position of the UK-based biotech to execute its four scientific programmes focused on viral […]

August 8, 2022

It has the potential to be a sizeable new indication for Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate, and central to AZ and Daiichi Sankyo’s hopes of unlocking multibillion-dollar sales for the drug. According to the FDA, out of the […]

February 10, 2022

The new vaccine – codenamed AZD2816 – started phase 2/3 trials as a booster dose for people vaccinated with Vaxzevria or mRNA vaccines from Pfizer/BioNTech and Moderna last June, when Beta was still the dominant SARS-CoV-2 variant of concern. In […]

December 6, 2021

Tenders to the offer fell below the 90% threshold needed to drive the merger through, and a key part of that was AZ’s refusal to back the offer from Advent International and Singapore’s sovereign wealth fund GIC, according to a […]

July 27, 2021

AZ’s buy into the programme comes a few weeks after Regeneron published findings in the journal Science suggesting that people with certain GPR75 mutations have 54% reduced risk of obesity, based on sequencing data from almost 650,000 people in the […]

July 15, 2021

J&J, AZ and the University of Oxford, alongside outside scientists, are planning to conduct early research into the potential of modifications to their vaccines to reduce or remove the risk of rare but serious blood clots associated with the jabs, […]

July 15, 2021

AZ and FibroGen are aiming for approval of roxadustat for the treatment of anaemia caused by chronic kidney disease (CKD). In briefing documents published ahead of a meeting of the Cardiovacular and Renal Drugs Advisory Committee meeting on 15 July, […]

June 22, 2021

The EU approval makes Koselugo (selumetinib) the first treatment option for children aged three and over with neurofibromatosis type 1 (NF1), a debilitating disease that affects one in 3,000 individuals worldwide. Up to half of patients with NF1 develop the […]